BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18087213)

  • 21. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase.
    Parkhurst MR; Riley JP; Igarashi T; Li Y; Robbins PF; Rosenberg SA
    Clin Cancer Res; 2004 Jul; 10(14):4688-98. PubMed ID: 15269141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changing patterns of dominant TCR usage with maturation of an EBV-specific cytotoxic T cell response.
    Annels NE; Callan MF; Tan L; Rickinson AB
    J Immunol; 2000 Nov; 165(9):4831-41. PubMed ID: 11046006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diepitope multiple antigen peptide of hTERT trigger stronger anti-tumor immune responses in vitro.
    Liao ZL; Luo G; Xie X; Tang XD; Bai JY; Guo H; Yang SM
    Int Immunopharmacol; 2013 Aug; 16(4):444-50. PubMed ID: 23714071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.
    Vonderheide RH; Domchek SM; Schultze JL; George DJ; Hoar KM; Chen DY; Stephans KF; Masutomi K; Loda M; Xia Z; Anderson KS; Hahn WC; Nadler LM
    Clin Cancer Res; 2004 Feb; 10(3):828-39. PubMed ID: 14871958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes.
    Arai J; Yasukawa M; Ohminami H; Kakimoto M; Hasegawa A; Fujita S
    Blood; 2001 May; 97(9):2903-7. PubMed ID: 11313288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity.
    Valmori D; Dutoit V; Schnuriger V; Quiquerez AL; Pittet MJ; Guillaume P; Rubio-Godoy V; Walker PR; Rimoldi D; Liénard D; Cerottini JC; Romero P; Dietrich PY
    J Immunol; 2002 Apr; 168(8):4231-40. PubMed ID: 11937585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
    Sensi M; Traversari C; Radrizzani M; Salvi S; Maccalli C; Mortarini R; Rivoltini L; Farina C; Nicolini G; Wölfel T
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5674-8. PubMed ID: 7777568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient.
    Knutson KL; Disis ML
    Hum Immunol; 2002 Jul; 63(7):547-57. PubMed ID: 12072190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines.
    Sørensen RB; Junker N; Kirkin A; Voigt H; Svane IM; Becker JC; thor Straten P; Andersen MH
    Cancer Immunol Immunother; 2009 May; 58(5):665-75. PubMed ID: 18828018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An antigen-targeted approach to adoptive transfer therapy of cancer.
    Valmori D; Pittet MJ; Rimoldi D; Liénard D; Dunbar R; Cerundolo V; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 1999 May; 59(9):2167-73. PubMed ID: 10232604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen.
    Mami-Chouaib F; Echchakir H; Dorothée G; Vergnon I; Chouaib S
    Immunol Rev; 2002 Oct; 188():114-21. PubMed ID: 12445285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uses of telomerase peptides in anti-tumor immune therapy.
    Li H; Katik I; Liu JP
    Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.
    Barfoed AM; Petersen TR; Kirkin AF; Thor Straten P; Claesson MH; Zeuthen J
    Scand J Immunol; 2000 Feb; 51(2):128-33. PubMed ID: 10652158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD2/LFA-3 or LFA-1/ICAM-1 but not CD28/B7 interactions can augment cytotoxicity by virus-specific CD8+ cytotoxic T lymphocytes.
    de Waal Malefyt R; Verma S; Bejarano MT; Ranes-Goldberg M; Hill M; Spits H
    Eur J Immunol; 1993 Feb; 23(2):418-24. PubMed ID: 7679643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myeloid dendritic cells loaded with dendritic tandem multiple antigenic telomerase reverse transcriptase (hTERT) epitope peptides: a potentially promising tumor vaccine.
    Niu BL; Du HM; Shen HP; Lian ZR; Li JZ; Lai X; Wei SD; Zou LQ; Gong JP
    Vaccine; 2012 May; 30(23):3395-404. PubMed ID: 22480929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas.
    Guerra N; Guillard M; Angevin E; Echchakir H; Escudier B; Moretta A; Chouaib S; Caignard A
    Blood; 2000 May; 95(9):2883-9. PubMed ID: 10779435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line.
    Santegoets SJ; Schreurs MW; Masterson AJ; Liu YP; Goletz S; Baumeister H; Kueter EW; Lougheed SM; van den Eertwegh AJ; Scheper RJ; Hooijberg E; de Gruijl TD
    Cancer Immunol Immunother; 2006 Dec; 55(12):1480-90. PubMed ID: 16468034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
    Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
    Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
    Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.